Bicara Therapeutics BCAX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's total liabilities & equity?
- Bicara Therapeutics (BCAX) reported total liabilities & equity of $553.6M in Q1 2026.
- How has Bicara Therapeutics's total liabilities & equity changed year-over-year?
- Bicara Therapeutics's total liabilities & equity increased by 15.8% year-over-year, from $478.08M to $553.6M.
- What is the long-term trend for Bicara Therapeutics's total liabilities & equity?
- Over 2 years (2023 to 2025), Bicara Therapeutics's total liabilities & equity has grown at a 35.7% compound annual growth rate (CAGR), from $233.98M to $430.99M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.